ALZpath announced expanded collaboration grants Alamar commercial rights to use ALZpath’s proprietary pTau217 antibody in blood-based diagnostic tests for clinical use. The update supports scaling commercialization of Alzheimer’s blood diagnostics using ALZpath’s intellectual property, which is a constructive development for the platform. No financial impact figures were provided in the release.
ALZpath announced expanded collaboration grants Alamar commercial rights to use ALZpath’s proprietary pTau217 antibody in blood-based diagnostic tests for clinical use. The update supports scaling commercialization of Alzheimer’s blood diagnostics using ALZpath’s intellectual property, which is a constructive development for the platform. No financial impact figures were provided in the release.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
